Quick Facts

• Relieves: Heartburn and acid indigestion.
• Manages: Symptoms of hyperacidity, including discomfort from excessive stomach acid.
• Action: Provides relief by neutralizing stomach acid and reducing acid production.

---

Kremil-S Advance is a medicinal product formulated for the management of symptoms associated with heartburn and acid indigestion. Its therapeutic effect is the relief of discomfort caused by hyperacidity—the presence of excessive stomach acid.

This medicine functions in two primary ways to alleviate gastrointestinal distress. First, it contains compounds that act as antacids, working to rapidly neutralize the acid that is already present in the stomach, thereby providing fast relief from irritation. Second, it includes an ingredient, famotidine, that belongs to a class of medicines known as H2-receptor antagonists, which reduce the production of stomach acid for a prolonged period. This dual-action approach helps manage the underlying cause of the symptoms.

The primary benefit of using Kremil-S Advance is the rapid and prolonged symptomatic relief of heartburn and discomfort related to acid reflux.

Regulatory References

1. NIH MedlinePlus guidance on acid reducers

Official Eligibility and Restrictions

Regulatory documentation defines specific eligibility rules for the use of Kremil-S Advance (Famotidine, Calcium Carbonate, and Magnesium Hydroxide combination).

---

Populations Approved for Use

The medicine is approved for use in adults and adolescents 12 years of age and over. Use in children under 12 years of age is not recommended, as safety and efficacy have not been established in this pediatric group.

---

Absolute Contraindications

Use of Kremil-S Advance is contraindicated in several specific populations, including:

• Patients with a known hypersensitivity (allergy) to famotidine or other acid reducers in the H₂-receptor antagonist class.
• Individuals who are concurrently using other acid reducers.
• Patients with documented moderate or severe renal failure (severe kidney disease) or severe hepatic impairment.

---

Conditional or Restricted Use

Patients must ask a health professional before use if they are pregnant or breast-feeding, or if they have pre-existing kidney disease. The medicine must also not be used if a patient is experiencing severe gastrointestinal symptoms, such as pain or trouble swallowing food, vomiting with blood, or bloody or black/tarry stools.

Interactions with other medicines and products

This combination product's official interaction profile is characterized by two distinct pharmacokinetic mechanisms: gastric pH alteration and cation binding.

---

Interaction scope

Category	Interaction Entities / Substances
Contraindicated Combinations	Ceftriaxone (IV) (risk of fatal precipitation); Eltrombopag (significant absorption decrease).
Exposure-Modifying Substances	Weak-Base Drugs (e.g., Atazanavir, Ketoconazole); Tetracycline and Quinolone antibiotics; Iron Supplements; Bisphosphonates (decreased absorption/efficacy).
Pharmacodynamic Interactions	Digoxin (may increase level/effect); Tizanidine (Famotidine alone is a weak CYP1A2 inhibitor, increasing Tizanidine concentration).

---

Official Interaction Statements

• Co-administration with Ceftriaxone (IV) is formally contraindicated due to the calcium component, which presents a documented risk of potentially fatal particulate precipitation.
• The absorption of Weak-Base Drugs is reduced because the combination increases gastric pH, resulting in reduced plasma concentrations of the co-administered drug.
• Timing separation is required for several substances: The antacid salts reduce the absorption of Tetracycline antibiotics (administer 1 hour before or 2 hours after) and Iron Supplements (administer 2 hours before or 3 hours after).
• In patients with severe renal impairment (creatinine clearance less than 10 mL/min), the systemic clearance of the active components, Famotidine and Magnesium Hydroxide, is reduced, leading to an increased risk of accumulation and potential for heightened interaction severity.

---

Connection to the overall interaction profile

Regulatory documentation defines this product’s interaction structure by the pH-altering effect of both Famotidine and the antacids, and the chelation properties of the antacid cations. This necessitates mandatory separation rules and specific prohibitions to mitigate the official risk of therapeutic failure or adverse precipitation.

How Kremil-S Advance Works

Immediate pH Neutralization

This mechanism involves the chemical interaction of basic Aluminum and Magnesium Hydroxides with Hydrochloric Acid ( HCl) present in the gastric lumen. This non-systemic acid-base reaction consumes free HCl molecules, resulting in an immediate increase in gastric pH.

Sustained Acid Secretion Blockade

The component Famotidine acts as a selective H2-receptor antagonist on the gastric parietal cells. By competitively binding to the H2 receptor, it interrupts the signal cascade that normally drives the activation of the proton pump. This action causes a prolonged modulation of the acid secretion pathway, which limits the total HCl output over time.

Physical Surface Modulation

, Dimethicone, the antiflatulent component, operates by changing the physical characteristics of the fluid within the gut. It lowers the surface tension of trapped gas bubbles, causing them to combine and dissipate, leading to a change in the physical characteristics and volume of gas in the gastrointestinal lumen.

Kremil-S Advance is approved for oral administration as a chewable tablet and is utilized on an as-needed basis for the high-level relief of symptoms related to gastric acid excess. The administration of this product is governed by specific procedural instructions derived from official labeling.

---

The key instruction for proper use is that the tablet must be fully chewed before it is swallowed. This requirement is mandatory for the oral dosage form to allow the antacid components to function correctly upon intake. The medicine is designed for intermittent use; the standard single dose for symptomatic relief is one tablet. A strict limit is placed on the total intake, with regulatory guidelines specifying that no more than two tablets may be taken within any 24-hour period.

---

This combination product is designated for short-term, self-care usage. The course duration for continuous administration as an over-the-counter medicine must not exceed 14 days. Should symptoms persist after this period, further professional evaluation is necessary, as the product is not indicated for long-term or maintenance regimens. It is officially indicated for use in adults and children 12 years of age and older. Furthermore, a high-level constraint on use involves individuals with impaired kidney function; use is generally not recommended in cases of moderate to severe kidney disease.

The official usage protocol defines a clear structure for its administration: chew the tablet, adhere to the daily maximum, and observe the two-week duration limit.

Recent Clinical Evidence

Phase 2 Trial: Acute Migraine Evaluation

Early research evaluated outcomes related to pain levels and time to relief in individuals experiencing acute migraines. The investigation included both oral and subcutaneous formulations of the compound.

• Sustained Pain Freedom: A key Phase 2 study of 300 participants focused on the endpoint of sustained pain freedom, which was defined as no pain recurrence within a 48-hour period. The primary measure evaluated was the rate of participants achieving pain freedom at two hours post-dose.
• Trial Parameters: Dose-ranging studies were conducted to compare different amounts of the compound. Observations related to the reported frequency of migraines were recorded during the 12-week trial period.

---

Safety and Tolerability Profile

The overall tolerability profile was monitored throughout all research phases. The most frequently reported side effects observed in the trials included nausea and dizziness. Tolerability was monitored by researchers throughout the study period.

• Potential Interactions: Research was conducted to assess potential metabolic interactions with common over-the-counter pain relievers.
• Special Populations: Specific criteria were applied regarding participation of individuals with pre-existing liver conditions, who were typically excluded from the primary trials or closely monitored.

---

Exploration in Other Headache Types

Research also evaluated outcomes related to chronic tension headaches. An open-label extension study followed a cohort of 50 participants for six months to assess usage over an extended period.

• Combination Evaluation: Research evaluated the relationship between the combination and reported patient sleep quality. The findings suggested that the timing of administration was a variable evaluated in the research, which was a factor considered in the analysis of the study outcomes.

---

Administration Methodology

The primary trials involved a study protocol for administration at the onset of migraine symptoms. Researchers observed participant adherence to the protocol as a part of the study design. The current body of evidence focuses on acute treatment; additional studies have been proposed to explore prophylactic (preventive) use.

Common questions about Kremil-S Advance (FAQ)

---

Q: Does Kremil-S Advance treat stomach ulcers or is it only for heartburn relief?

Official product information states that this OTC combination is indicated for the relief of common symptoms like heartburn, acid indigestion, and sour stomach. While the active ingredient Famotidine may be used in other products to treat stomach ulcers, the OTC label for this combination product does not include that indication.

---

Q: Is Kremil-S Advance effective for treating gas and general bloating?

The labeled intent of the core active ingredients is to address symptoms caused by excess stomach acid. Official regulatory documents list gas-related discomfort, such as flatulence, as an undesirable effect associated with the Famotidine component.

---

Q: Why does Kremil-S Advance contain three different active ingredients working together?

The medicine contains three active components to achieve a dual action on stomach acid. It combines Famotidine (an H2-receptor antagonist) to reduce acid production over time with two antacids ( Calcium Carbonate and Magnesium Hydroxide) to provide rapid pH neutralization.

---

Q: Is Kremil-S Advance the same as other over-the-counter Famotidine medications?

This product is classified as an H2-antagonist combination product. This means it contains the acid reducer Famotidine along with the two antacid salts, Calcium Carbonate and Magnesium Hydroxide. Other over-the-counter Famotidine products may contain only Famotidine or a different combination of ingredients.

---

Q: Why is Kremil-S Advance supplied as a chewable tablet instead of a swallowable pill?

The chewable form facilitates the immediate release of the antacid components. The regulatory administration instructions indicate that the tablet must be fully chewed before swallowing, which is necessary for the antacids to begin neutralizing stomach acid on contact.

---

Q: How fast can I expect Kremil-S Advance to start working after chewing the tablet?

Official data indicates the product provides a rapid onset of action. This fast relief is primarily attributed to the antacid components, which begin neutralizing stomach acid quickly after the tablet is chewed.

---

Q: How long does the heartburn relief from one tablet of Kremil-S Advance typically last?

The Famotidine component is associated with a prolonged duration of effect, which helps to extend the time of symptom relief. This dual action is intended to provide sustained acid management.

---

Q: Does the Famotidine component in the tablet take longer to start working than the antacids?

Official pharmacological documents indicate the combination is designed to provide the rapid onset of action from the antacids, complemented by the prolonged duration of effect from the Famotidine component. The antacids work to neutralize acid quickly.

---

Q: Is there a risk of high calcium levels from taking Kremil-S Advance regularly?

Regulatory warnings mention that over-consumption of the calcium component may result in a serious condition called hypercalcemia (high blood calcium levels). Hypercalcemia may be associated with symptoms such as changes in mental status, nausea, or vomiting.

---

Q: What side effects are associated specifically with the Famotidine ingredient?

Undesirable effects associated with the Famotidine component include headaches, dizziness, and central nervous system ( CNS) effects like confusion, especially in older adults or those with renal impairment. Loss of taste and kidney problems have also been reported.

---

Q: Does Kremil-S Advance contain aluminum, like some other older antacids?

Based on the official label, Aluminum is not listed as an active ingredient in this combination product. The active components are Famotidine, Calcium Carbonate, and Magnesium Hydroxide.

---

Q: Is it true that taking this medicine regularly could increase the risk of kidney problems?

Regulatory documents note that patients with pre-existing moderate to severe kidney disease are at an increased risk of systemic effects and accumulation of the medicine's components. This increased risk is the reason the product label includes a caution regarding use in patients with kidney function concerns.

---

Q: Can taking too many tablets of Kremil-S Advance cause an increase in acid production later on?

Official information reports that Calcium Carbonate, an active ingredient, can rarely stimulate a phenomenon called acid rebound. This acid rebound may potentially cause the stomach to produce more acid after the initial neutralizing effect has passed.

---

Q: Can Kremil-S Advance affect my blood pressure?

Official undesirable effects listed for the Famotidine component include the occurrence of hypertension (high blood pressure).

---

Q: Does Kremil-S Advance interact with blood thinners like warfarin?

Because this medicine may affect the absorption of other drugs, the product label includes a general caution regarding its use with prescription medications. This is especially true for drugs like Warfarin, where therapy requires careful monitoring.

---

Q: Can this medicine interfere with the absorption or effectiveness of thyroid medication (e.g., levothyroxine)?

Regulatory documents indicate that the antacid components can decrease the effects of Levothyroxine (thyroid medication). The interaction profile notes that a time separation of at least four hours is generally required when taking Levothyroxine with this medicine.

---

Q: Is Kremil-S Advance considered safe for use by pregnant or breastfeeding women?

The official patient label advises consulting a health professional before use if a person is pregnant or breastfeeding. The Famotidine component is known to be excreted in human milk, and risks to the nursing infant should be considered.

---

Q: Is Kremil-S Advance an appropriate treatment option for patients diagnosed with GERD?

This OTC product is indicated for the relief of common acid-related symptoms like heartburn and sour stomach. The OTC product is not specifically indicated for the clinical diagnosis of GERD (Gastroesophageal Reflux Disease).

---

Q: Can a person with diabetes safely use Kremil-S Advance?

The official labeling does not specify a direct interaction with diabetes medications. However, official regulatory guidance includes a general caution for patients taking any prescription drug, including those for diabetes, regarding use of this product.

---

Q: Is Kremil-S Advance considered a 'stronger' medicine compared to single-ingredient antacids?

The product is formulated with two classes of ingredients: antacids and an H2-receptor antagonist. This dual mechanism is designed to provide both rapid relief from the antacids and a prolonged effect from Famotidine.

---

Q: What research evidence supports the specific combination of Famotidine, Calcium Carbonate, and Magnesium Hydroxide?

Research supports the medicine's dual-action mechanism. The combination is studied for its ability to provide both immediate acid neutralization ( Magnesium Hydroxide/Calcium Carbonate) and sustained acid reduction ( Famotidine).

---

Q: What is the simple explanation for the medical term 'H2-receptor antagonist' found in the description?

An H2-receptor antagonist is a class of medicine that blocks the signals that normally tell the stomach to produce acid. The medicine works by binding to H2 receptors on the stomach’s acid-producing cells, effectively interfering with the process of acid creation.

---

Q: Does this medicine offer any dietary benefits, like extra calcium for bone health?

Although each tablet contains measured amounts of calcium and magnesium, the product is officially indicated only for heartburn relief. It is not approved or listed as a dietary supplement for bone health or other nutritional purposes.

---

Q: Can taking Kremil-S Advance potentially cause a person to gain or lose weight?

Unexplained weight loss is mentioned in regulatory documents as a serious symptom that warrants attention from a health professional. Weight gain is not directly listed as an official side effect.

---

Q: What is the 'milk-alkali syndrome' that is sometimes mentioned in relation to the ingredients?

The milk-alkali syndrome ( MAS) is a condition related to excessive intake of calcium components, which is a risk characteristic of hypercalcemia. This condition is mentioned in the context of the risk of hypercalcemia, particularly for patients with compromised kidney function.

---

Q: Where can a patient find the most recent official Patient Information Leaflet for Kremil-S Advance?

Official consumer labeling and drug information can be accessed on government websites, such as DailyMed ( NIH), which publishes the FDA-approved patient labeling.

---

Q: Is it normal to experience a metallic taste after chewing Kremil-S Advance?

Official regulatory documents list changes in taste, also known as dysgeusia, and loss of taste as undesirable effects associated with the Famotidine component.

---

Q: Does taking Kremil-S Advance with food affect how quickly it works?

The product label specifies the administration condition as being on an empty stomach. This condition requires taking the tablet approximately one hour before or two hours after a meal.

---

Q: Can I take Kremil-S Advance at the same time as my daily vitamins or supplements?

Official warnings include a caution regarding use with all drugs, vitamins, and herbal supplements. Antacids and acid reducers may affect the absorption and effectiveness of many other products.

How to Store and Dispose of Kremil-S Advance

Official regulatory guidelines specify how this medicine must be stored and discarded. For stability, store Kremil-S Advance at temperatures not exceeding 30 C and protect it from direct light and moisture. Do not use the medicine after the expiry date printed on the label.

To ensure safety, the product must always be kept out of the reach and sight of children.

Regarding disposal, do not flush this medicine down a toilet or pour it into a drain unless instructed to do so by the labeling. The preferred method is to utilize a community drug take-back program. If one is unavailable, remove the medicine from its original container, mix it with an undesirable substance like used coffee grounds or cat litter, seal it in a bag, and then discard it in the household trash.